title: Roadblocks to success for RNA CARs in solid tumors.
abstract: While CAR therapy has begun to demonstrate efficacy, cell-engineering techniques that result in permanent genomic modification carry several safety concerns. CAR expression driven by RNA creates a platform for delivery of highly-active cell therapy while avoiding long-term CAR-driven toxicity. Using models of pediatric neuroblastoma, we have found that RNA CAR T cell activity is limited by ineffective tumor infiltration.
authors.affiliation: Department of Medicine; Perelman School of Medicine at the University of Pennsylvania ; Philadelphia, PA USA.
authors.forename: Nathan
authors.initials: N
authors.lastname: Singh
authors.affiliation: Division of Oncology; Children's Hospital of Philadelphia ; Philadelphia, PA USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Barrett
authors.affiliation: Division of Oncology; Children's Hospital of Philadelphia ; Philadelphia, PA USA.
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
keywords: GD2; Lenti CAR, lentivirally-modified chimeric antigen receptor T cell; RNA; RNA CAR, RNA-modified chimeric antigen receptor T cell; chimeric antigen receptors; pediatrics; solid tumors